{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T18:51:47Z","timestamp":1786819907870,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The broadly neutralizing antibody (bNAb) CAP256-VRC26.25 has exceptional potency against HIV-1 and has been considered for clinical use. During the characterization and production of this bNAb, we observed several unusual features. First, the antibody appeared to adhere to pipette tips, requiring tips to be changed during serial dilution to accurately measure potency. Second, during production scale-up, proteolytic cleavage was discovered to target an extended heavy chain loop, which was attributed to a protease in spent medium from 2-week culture. To enable large scale production, we altered the site of cleavage via a single amino acid change, K100mA. The resultant antibody retained potency and breadth while avoiding protease cleavage. We also added the half-life extending mutation LS, which improved the in vivo persistence in animal models, but did not impact neutralization activity; we observed the same preservation of neutralization for bNAbs VRC01, N6, and PGDM1400 with LS on a 208-virus panel. The final engineered antibody, CAP256V2LS, retained the extraordinary neutralization potency of the parental antibody, had a favorable pharmacokinetic profile in animal models, and was negative in in vitro assessment of autoreactivity. CAP256V2LS has the requisite potency, developability and suitability for scale-up, allowing its advancement as a clinical candidate.<\/jats:p>","DOI":"10.1038\/s41598-022-22435-2","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T15:04:27Z","timestamp":1666710267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life"],"prefix":"10.1038","volume":"12","author":[{"given":"Baoshan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Gollapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijy","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland F.","family":"Damron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisha","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangaiarkarasi","family":"Asokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Sung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarendra","family":"Pegu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara W.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera B.","family":"Ivleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Louder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hsiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian B.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. Paula","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Doria-Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"issue":"Suppl 7","key":"22435_CR1","doi-asserted-by":"crossref","first-page":"e25829","DOI":"10.1002\/jia2.25829","volume":"24","author":"MD Miner","year":"2021","unstructured":"Miner, M. D., Corey, L. & Montefiori, D. Broadly neutralizing monoclonal antibodies for HIV prevention. J. Int. AIDS Soc. 24(Suppl 7), e25829 (2021).","journal-title":"J. Int. AIDS Soc."},{"key":"22435_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"22435_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/JVI.01791-15","volume":"90","author":"NA Doria-Rose","year":"2016","unstructured":"Doria-Rose, N. A. et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 90, 76\u201391 (2016).","journal-title":"J. Virol."},{"key":"22435_CR4","doi-asserted-by":"publisher","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","volume":"12","author":"K Wagh","year":"2016","unstructured":"Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog. 12, e1005520 (2016).","journal-title":"PLoS Pathog."},{"key":"22435_CR5","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s13361-018-1968-0","volume":"29","author":"VB Ivleva","year":"2018","unstructured":"Ivleva, V. B. et al. Investigation of sequence clipping and structural heterogeneity of an HIV broadly neutralizing antibody by a comprehensive LC-MS analysis. J. Am. Soc. Mass Spectrom. 29, 1512\u20131523 (2018).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"22435_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-1-4939-7312-5_12","volume":"1674","author":"Y Fan","year":"2018","unstructured":"Fan, Y., Ley, D. & Andersen, M. R. Fed-batch CHO cell culture for lab-scale antibody production. Methods Mol. Biol. 1674, 147\u2013161 (2018).","journal-title":"Methods Mol. Biol."},{"key":"22435_CR7","doi-asserted-by":"publisher","first-page":"10469","DOI":"10.1007\/s00253-018-9388-4","volume":"102","author":"I Martinez-Monge","year":"2018","unstructured":"Martinez-Monge, I. et al. A new strategy for fed-batch process control of HEK293 cell cultures based on alkali buffer addition monitoring: Comparison with O.U.R. dynamic method. Appl. Microbiol. Biotechnol. 102, 10469\u201310483 (2018).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"22435_CR8","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.1007\/s00216-019-01995-9","volume":"411","author":"CX Cai","year":"2019","unstructured":"Cai, C. X. et al. Characterization of AEBSF-antibody modifications for a protease inhibitor supplementation strategy. Anal. Bioanal. Chem. 411, 6111\u20136118 (2019).","journal-title":"Anal. Bioanal. Chem."},{"key":"22435_CR9","doi-asserted-by":"publisher","first-page":"197672","DOI":"10.1016\/j.virusres.2019.197672","volume":"271","author":"L Sreelatha","year":"2019","unstructured":"Sreelatha, L. et al. Serine protease inhibitor AEBSF reduces dengue virus infection via decreased cholesterol synthesis. Virus Res. 271, 197672 (2019).","journal-title":"Virus Res."},{"key":"22435_CR10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/btpr.1953","volume":"30","author":"W Kelly","year":"2014","unstructured":"Kelly, W. et al. Understanding and modeling alternating tangential flow filtration for perfusion cell culture. Biotechnol. Prog. 30, 1291\u20131300 (2014).","journal-title":"Biotechnol. Prog."},{"key":"22435_CR11","doi-asserted-by":"publisher","first-page":"e2831","DOI":"10.1002\/btpr.2831","volume":"35","author":"J Hong","year":"2019","unstructured":"Hong, J. et al. Development of an alternating tangential flow (ATF) perfusion-based transient gene expression (TGE) bioprocess for universal influenza vaccine. Biotechnol. Prog. 35, e2831 (2019).","journal-title":"Biotechnol. Prog."},{"key":"22435_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3296","author":"D Gollapudi","year":"2022","unstructured":"Gollapudi, D. et al. Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development. Biotechnol. Prog. https:\/\/doi.org\/10.1002\/btpr.3296 (2022).","journal-title":"Biotechnol. Prog."},{"key":"22435_CR13","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1038\/srep07331","volume":"4","author":"Z Pan","year":"2014","unstructured":"Pan, Z. et al. Systematic analysis of the in situ crosstalk of tyrosine modifications reveals no additional natural selection on multiply modified residues. Sci. Rep. 4, 7331 (2014).","journal-title":"Sci. Rep."},{"key":"22435_CR14","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1126\/scitranslmed.aal1321","volume":"9","author":"B Julg","year":"2017","unstructured":"Julg, B. et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci. Transl. Med. 9, 1321 (2017).","journal-title":"Sci. Transl. Med."},{"key":"22435_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159 (2010).","journal-title":"Nat. Biotechnol."},{"key":"22435_CR16","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","volume":"15","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).","journal-title":"PLoS Med."},{"key":"22435_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"22435_CR18","doi-asserted-by":"publisher","first-page":"8433","DOI":"10.1038\/s41598-022-12423-x","volume":"12","author":"CX Cai","year":"2022","unstructured":"Cai, C. X. et al. Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency. Sci. Rep. 12, 8433 (2022).","journal-title":"Sci. Rep."},{"key":"22435_CR19","doi-asserted-by":"publisher","first-page":"107488","DOI":"10.1016\/j.celrep.2020.03.052","volume":"31","author":"J Gorman","year":"2020","unstructured":"Gorman, J. et al. Structure of super-potent antibody CAP256-VRC26.25 in complex with HIV-1 envelope reveals a combined mode of trimer-apex recognition. Cell Rep. 31, 107488 (2020).","journal-title":"Cell Rep."},{"key":"22435_CR20","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","volume":"8","author":"LB Avery","year":"2016","unstructured":"Avery, L. B. et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs 8, 1064\u20131078 (2016).","journal-title":"MAbs"},{"key":"22435_CR21","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","volume":"88","author":"RS Rudicell","year":"2014","unstructured":"Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669\u201312682 (2014).","journal-title":"J. Virol."},{"key":"22435_CR22","doi-asserted-by":"publisher","first-page":"1946918","DOI":"10.1080\/19420862.2021.1946918","volume":"13","author":"YD Kwon","year":"2021","unstructured":"Kwon, Y. D. et al. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. MAbs 13, 1946918 (2021).","journal-title":"MAbs"},{"key":"22435_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4161\/mabs.3.3.15608","volume":"3","author":"J Vlasak","year":"2011","unstructured":"Vlasak, J. & Ionescu, R. Fragmentation of monoclonal antibodies. MAbs 3, 253\u2013263 (2011).","journal-title":"MAbs"},{"key":"22435_CR24","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","volume":"6","author":"MR Gaudinski","year":"2019","unstructured":"Gaudinski, M. R. et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: A phase 1 dose-escalation clinical trial. Lancet HIV 6, e667\u2013e679 (2019).","journal-title":"Lancet HIV"},{"key":"22435_CR25","doi-asserted-by":"crossref","first-page":"e042247","DOI":"10.1136\/bmjopen-2020-042247","volume":"10","author":"S Mahomed","year":"2020","unstructured":"Mahomed, S. et al. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: Study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ Open 10, e042247 (2020).","journal-title":"BMJ Open"},{"key":"22435_CR26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1126\/science.aae0474","volume":"352","author":"R Kong","year":"2016","unstructured":"Kong, R. et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352, 828\u2013833 (2016).","journal-title":"Science"},{"key":"22435_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/nm.3963","volume":"21","author":"JN Bhiman","year":"2015","unstructured":"Bhiman, J. N. et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat. Med. 21, 1332\u20131336 (2015).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22435-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22435-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22435-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T14:44:22Z","timestamp":1701269062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22435-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22435"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22435-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"7 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NDR, JG, PDK, and JRM are co-inventors on a patent including the CAP256-VRC26.25 antibody, US application 16\/718,322 pending. All other authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17876"}}